AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AZN
- Rev/Share 18.5878
- Book/Share 14.7006
- PB 6.4502
- Debt/Equity 0.7118
- CurrentRatio 0.8792
- ROIC 0.121
- MktCap 293468667875.0
- FreeCF/Share 3.5646
- PFCF 26.3271
- PE 31.4912
- Debt/Assets 0.2854
- DivYield 0.0165
- ROE 0.218
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AZN | Jefferies | -- | Buy | -- | -- | Oct. 27, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Oct. 16, 2025 |
| Initiation | AZN | Exane BNP Paribas | -- | Outperform | -- | $75 | April 15, 2025 |
| Upgrade | AZN | UBS | Neutral | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | AZN | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Sept. 13, 2024 |
News
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.
Read More
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
LSEG, Rolls-Royce, AstraZeneca and Rightmove spotlighted as investment bank eyes potential winners for 2026
Published: December 24, 2025 by: Proactive Investors
Sentiment: Positive
The festive period is, for some, a time for taking stock of what's happened in the past year - for others, though, its a time to pick stocks for the year ahead. So it is, then, that it's the season for looking ahead.
Read More
ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Negative
AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
Read More
Here's Why Astrazeneca (AZN) is a Strong Value Stock
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
5 Big Drug Stocks That May Continue to Outperform in 2026
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Read More
AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca's Enhertu wins FDA Breakthrough tag for expanded use in breast cancer, while a late-stage study on ceralasertib + Imfinzi in lung cancer misses its goal.
Read More
AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial
Published: December 22, 2025 by: WSJ
Sentiment: Negative
The pharmaceutical company said its ceralasertib combination didn't meet the primary goal of a late-stage clinical trial for advanced lung cancer.
Read More
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial
Published: December 22, 2025 by: Reuters
Sentiment: Negative
AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival in patients with previously treated advanced non‑small cell lung cancer.
Read More
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
Published: December 19, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
Read More
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma
Published: December 10, 2025 by: Seeking Alpha
Sentiment: Neutral
AstraZeneca (AZN) offers a rare, secular growth profile in biopharma, underpinned by a diversified commercial asset base and layered patent expirations. AZN faces a minor patent cliff, with most key products' loss of exclusivity in the 2030s, and rapidly growing therapies offsetting near-term risks. The pipeline is robust and diversified, targeting 20 new molecular entities by 2030, supporting management's ambition to nearly double revenues to $80B.
Read More
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.
Read More
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
Published: December 02, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pressure. The Prescription Drug User Fee Act (PDUFA) date is anticipated during the second quarter of 202.
Read More
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
AstraZeneca or Merck: Which Oncology Giant Has the Edge?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
Read More
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
Published: November 26, 2025 by: CNBC
Sentiment: Neutral
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from 2027, including Novo Nordisk's mega bestseller Ozempic which will see a 71% discount to its list price.
Read More
AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows
Published: November 24, 2025 by: Benzinga
Sentiment: Positive
Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ: AZN), initially established in March 2025.
Read More
AstraZeneca to invest $2 billion as part of US manufacturing push
Published: November 21, 2025 by: Reuters
Sentiment: Positive
AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabilities in the U.S. by 2030.
Read More
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
Published: November 21, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials. The investment will support 2,600 jobs across the two sites in the state includin.
Read More
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
Published: November 10, 2025 by: Benzinga
Sentiment: Positive
AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well as safety and tolerability in participants with resistant hypertension.
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Pascal Claude Roland Soriot
- Employees 94300